The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.
After Merck's feed additive Zilmax was pulled from the market on side effect concerns last year, the company embarked on a comprehensive review. The results are in, and Merck has concluded the product is safe when consumed as detailed on the label.
Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which has been investing heavily in its cancer drug pipeline, is turning over a pair of early-stage drug candidates to see if Bind's delivery technology can amp up their efficacy.
When it comes to cattle feed additive Zilmax, pulled from the market last year on concerning side-effect reports, there's nothing to worry about, Merck says. After a comprehensive review, the drugmaker has determined the product is safe when used according to its label. Now it just has to convince the meat-packing industry.
A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.
Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of...
It has been a roller-coaster ride of a year for Merck, complete with M&A and corporate bloodletting intended to swing the company's numbers northward. Part of the drugmaker's ongoing turnaround plan could be paying off, as Merck announced third quarter earnings that beat analysts' expectations. But the company also reported slumping sales of some of its standout products due to hep C competitors and patent expirations, signaling more work in the months to come.
With the goal line for lung cancer in sight at the FDA as it races with an ambitious R&D team at Bristol-Myers Squibb, Merck has grabbed bragging rights to the agency's breakthrough drug designation for the checkpoint inhibitor pembrolizumab (Keytruda) for that golden market opportunity.
PetMed Express CEO Menderes Akdag raised a few eyebrows when he blamed his company's missed quarterly profit and sales targets on the weather.
Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.